ROYCE & ASSOCIATES LP - NEOLEUKIN THERAPEUTICS INC ownership

Quarter-by-quarter ownership
ROYCE & ASSOCIATES LP ownership history of NEOLEUKIN THERAPEUTICS INC
ValueSharesWeighting
Q3 2022$93,000
-38.0%
145,3970.0%0.00%
-50.0%
Q2 2022$150,000
-45.1%
145,3970.0%0.00%0.0%
Q1 2022$273,000
-61.1%
145,3970.0%0.00%
-60.0%
Q4 2021$701,000
-33.3%
145,3970.0%0.01%
-37.5%
Q3 2021$1,051,000
-21.7%
145,3970.0%0.01%
-11.1%
Q2 2021$1,342,000
-25.0%
145,3970.0%0.01%
-25.0%
Q1 2021$1,790,000
-12.7%
145,3970.0%0.01%
-29.4%
Q4 2020$2,050,000
+17.5%
145,3970.0%0.02%
-10.5%
Q3 2020$1,745,000
-27.7%
145,3970.0%0.02%
-29.6%
Q2 2020$2,414,000
+45.9%
145,3970.0%0.03%
+17.4%
Q1 2020$1,655,000
-7.6%
145,3970.0%0.02%
+43.8%
Q4 2019$1,791,000
+332.6%
145,3970.0%0.02%
+300.0%
Q3 2019$414,000145,3970.00%
Other shareholders
NEOLEUKIN THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Opaleye Management Inc. 1,047,300$5,048,0001.07%
ACT CAPITAL MANAGEMENT, LLC 212,500$1,024,0000.74%
Redmile Group, LLC 3,490,835$16,826,0000.38%
Kynam Capital Management, LP 147,000$709,0000.38%
EcoR1 Capital, LLC 860,619$4,148,0000.13%
Baker Brothers Advisors 3,821,740$18,421,0000.09%
GSA CAPITAL PARTNERS LLP 130,899$631,0000.08%
Sio Capital Management, LLC 38,312$185,0000.06%
Highland Private Wealth Management 46,999$227,0000.03%
XTX Topco Ltd 10,018$48,0000.03%
View complete list of NEOLEUKIN THERAPEUTICS INC shareholders